Jeffrey A Lieberman

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. ncbi Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine
    Jeffrey A Lieberman
    Department of Psychiatry, CB 7160, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7160, USA
    Neuropsychopharmacology 28:995-1003. 2003
  2. ncbi Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic
    T Scott Stroup
    Department of Psychiatry, University of North Carolina at Chapel Hill, CB 7160, Chapel Hill, NC 27599 7160, USA
    Am J Psychiatry 163:611-22. 2006
  3. ncbi Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia
    Stanley N Caroff
    Department of Psychiatry, Veterans Affairs Medical Center and University of Pennsylvania School of Medicine, Philadelphia, USA
    J Clin Psychiatry 72:295-303. 2011
  4. ncbi Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial
    Deborah A Perlick
    Department of Psychiatry, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, New York 10029 6574, USA
    Schizophr Res 116:118-25. 2010
  5. ncbi Results of phase 3 of the CATIE schizophrenia trial
    T Scott Stroup
    Department of Psychiatry, School of Medicine, University of North Carolina at Chapel Hill, USA
    Schizophr Res 107:1-12. 2009
  6. ncbi Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode
    Diana O Perkins
    Department of Psychiatry, C.B.# 7160, University of North Carolina School of Medicine, Chapel Hill, 27599-7160, USA
    Schizophr Res 83:53-63. 2006
  7. ncbi Effectiveness of switching antipsychotic medications
    Susan M Essock
    Department of Psychiatry, Division of Health Services Research, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    Am J Psychiatry 163:2090-5. 2006
  8. ncbi Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial
    Richard S E Keefe
    Department of Psychiatry, John Umstead Hospital, Duke University Medical Center, Durham, NC 27710, USA
    Arch Gen Psychiatry 64:633-47. 2007
  9. ncbi Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
    Jeffrey A Lieberman
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute, New York, NY 10032, USA
    N Engl J Med 353:1209-23. 2005
  10. ncbi Antipsychotic drug effects on brain morphology in first-episode psychosis
    Jeffrey A Lieberman
    Departments of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC, USA
    Arch Gen Psychiatry 62:361-70. 2005

Detail Information

Publications124 found, 100 shown here

  1. ncbi Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine
    Jeffrey A Lieberman
    Department of Psychiatry, CB 7160, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7160, USA
    Neuropsychopharmacology 28:995-1003. 2003
    ..Longer duration of untreated psychosis was associated with lower odds of achieving remission...
  2. ncbi Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic
    T Scott Stroup
    Department of Psychiatry, University of North Carolina at Chapel Hill, CB 7160, Chapel Hill, NC 27599 7160, USA
    Am J Psychiatry 163:611-22. 2006
    ..This randomized, double-blind study compared olanzapine, quetiapine, risperidone, and ziprasidone in patients who had just discontinued a different atypical antipsychotic...
  3. ncbi Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia
    Stanley N Caroff
    Department of Psychiatry, Veterans Affairs Medical Center and University of Pennsylvania School of Medicine, Philadelphia, USA
    J Clin Psychiatry 72:295-303. 2011
    ..We compared the response to antipsychotic treatment between patients with and without tardive dyskinesia (TD) and examined the course of TD...
  4. ncbi Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial
    Deborah A Perlick
    Department of Psychiatry, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, New York 10029 6574, USA
    Schizophr Res 116:118-25. 2010
    ..This study evaluated the effectiveness of first- and second-generation antipsychotics in reducing family burden associated with schizophrenia...
  5. ncbi Results of phase 3 of the CATIE schizophrenia trial
    T Scott Stroup
    Department of Psychiatry, School of Medicine, University of North Carolina at Chapel Hill, USA
    Schizophr Res 107:1-12. 2009
    ..We describe the characteristics of the patients who selected each treatment option and their outcomes...
  6. ncbi Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode
    Diana O Perkins
    Department of Psychiatry, C.B.# 7160, University of North Carolina School of Medicine, Chapel Hill, 27599-7160, USA
    Schizophr Res 83:53-63. 2006
    ....
  7. ncbi Effectiveness of switching antipsychotic medications
    Susan M Essock
    Department of Psychiatry, Division of Health Services Research, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    Am J Psychiatry 163:2090-5. 2006
    ....
  8. ncbi Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial
    Richard S E Keefe
    Department of Psychiatry, John Umstead Hospital, Duke University Medical Center, Durham, NC 27710, USA
    Arch Gen Psychiatry 64:633-47. 2007
    ..The relative effect of the second-generation (atypical) antipsychotic drugs and older agents on neurocognition has not been comprehensively determined...
  9. ncbi Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
    Jeffrey A Lieberman
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute, New York, NY 10032, USA
    N Engl J Med 353:1209-23. 2005
    ..We compared a first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study...
  10. ncbi Antipsychotic drug effects on brain morphology in first-episode psychosis
    Jeffrey A Lieberman
    Departments of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC, USA
    Arch Gen Psychiatry 62:361-70. 2005
    ..This raises the possibility that antipsychotics might alter such pathomorphologic progression in early-stage schizophrenia...
  11. ncbi Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study
    Diana O Perkins
    Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, USA
    J Clin Psychiatry 69:106-13. 2008
    ..To evaluate predictors of treatment discontinuation against medical advice and poor medication adherence among first-episode patients treated with olanzapine, quetiapine, or risperidone...
  12. ncbi Typical and atypical antipsychotic drug effects on locomotor hyperactivity and deficits in sensorimotor gating in a genetic model of NMDA receptor hypofunction
    Gary E Duncan
    Department of Psychiatry, University of North Carolina at Chapel Hill, USA
    Pharmacol Biochem Behav 85:481-91. 2006
    ..Since both haloperidol and the atypical drugs increased PPI, it is likely that D2 dopamine receptor blockade is responsible for the drug effects on sensorimotor gating...
  13. ncbi The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial
    David L Penn
    University of North Carolina Chapel Hill, Department of Psychology, Davie Hall, Chapel Hill, NC 27599 3270, USA
    Schizophr Res 115:17-23. 2009
    ..Greater improvement in emotion perception at 2 months was significantly predicted by lower baseline emotion perception and higher baseline neurocognitive functioning, and marginally predicted by less time on an antipsychotic...
  14. ncbi Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study
    Jonathan M Meyer
    Department of Psychiatry, University of California at San Diego, USA
    Biol Psychiatry 66:1013-22. 2009
    ..Despite the known CV effects of atypical antipsychotics, there is limited prospective data on IM changes during treatment...
  15. ncbi Prenatal and neonatal brain structure and white matter maturation in children at high risk for schizophrenia
    John H Gilmore
    Conte Schizophrenia Research Center and Department of Psychiatry, University of North Carolina at Chapel Hill, NC 27599 7160, USA
    Am J Psychiatry 167:1083-91. 2010
    ..This study was conducted to identify structural brain abnormalities in the prenatal and neonatal periods associated with genetic risk for schizophrenia...
  16. ncbi A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia
    Robert W Buchanan
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Maple and Locust Streets, Baltimore, MD 21228, USA
    Biol Psychiatry 69:442-9. 2011
    ..The current study was designed to further examine the efficacy and safety of MK-0777 for the treatment of cognitive impairments in schizophrenia...
  17. ncbi Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia
    Mark Olfson
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY, USA
    Schizophr Bull 38:845-53. 2012
    ..No significant differences were detected in risk of either adverse outcome across 5 commonly prescribed second-generation antipsychotic medications...
  18. ncbi Pro-apoptotic Par-4 and dopamine D2 receptor in temporal cortex in schizophrenia, bipolar disorder and major depression
    Leisa A Glantz
    Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Schizophr Res 118:292-9. 2010
    ..Changes in the Par-4/D2DR signaling pathway represent a novel mechanism that may link apoptotic and dopamine signaling pathways in major depression and schizophrenia...
  19. ncbi Amphetamine-induced Fos is reduced in limbic cortical regions but not in the caudate or accumbens in a genetic model of NMDA receptor hypofunction
    Seiya Miyamoto
    Department of Psychiatry, the Mental Health and Neuroscience Clinical Research Center, USA
    Neuropsychopharmacology 29:2180-8. 2004
    ..The results suggest a neuroanatomically selective activation deficit to amphetamine challenge in the NR1-deficient mice...
  20. ncbi Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study
    Jayendra K Patel
    Department of Psychiatry, University of Massachusetts Medical School, Worcester, MA 01605, USA
    Schizophr Res 111:9-16. 2009
    ..To further define the metabolic profiles of second-generation antipsychotics during the treatment of young patients with early psychosis, with a view to better inform prescribing clinicians...
  21. ncbi A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial
    Linmarie Sikich
    Department of Psychiatry, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7160, USA
    Neuropsychopharmacology 29:133-45. 2004
    ..However, youth treated with risperidone and olanzapine experienced weight gain and extrapyramidal effects that appear more prevalent and severe than reported in adults...
  22. ncbi Neonatal neurosteroid administration results in development-specific alterations in prepulse inhibition and locomotor activity: neurosteroids alter prepulse inhibition and locomotor activity
    Samantha S Gizerian
    Curriculum in Neurobiology and Department of Psychiatry, University of North Carolina at Chapel Hill, 7023 Neurosciences Hospital, Chapel Hill, NC 27599, USA
    Psychopharmacology (Berl) 186:334-42. 2006
    ..The temporal exposure differences (P2 vs P5) and ontological-dependent effects (P20 and P80, but not P40 or P60) suggest critical windows of vulnerability to neurosteroid insult across development...
  23. ncbi Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial
    Ragy R Girgis
    Department of Psychiatry, Columbia University, College of Physicians and Surgeons and New York State Psychiatric Institute, New York, USA
    Br J Psychiatry 199:281-8. 2011
    ..The differential effects of so-called 'first- and second generation' antipsychotic medications, when given in the first episode, on the long-term outcome of schizophrenia remain to be elucidated...
  24. ncbi The impact of obesity on health care costs among persons with schizophrenia
    Lydia A Chwastiak
    Department of Psychiatry, Yale School of Medicine, New Haven, CT 06519, USA
    Gen Hosp Psychiatry 31:1-7. 2009
    ..Obesity is the second leading cause of preventable death in the United States and is twice as common among individuals with schizophrenia as the general population...
  25. ncbi Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine
    Karen A Graham
    Department of Psychiatry, CB 7160, UNC Neurosciences Hospital, Chapel Hill, NC 27599 7160, USA
    Am J Psychiatry 162:1744-6. 2005
    ..This study sought to determine if amantadine affects weight gain in psychiatric patients taking olanzapine...
  26. ncbi No association of the serotonin transporter polymorphisms 5-HTTLPR and RS25531 with schizophrenia or neurocognition
    Thomas I Konneker
    Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7264, USA
    Am J Med Genet B Neuropsychiatr Genet 153:1115-7. 2010
    ..67 and negative symptoms P = 0.46). We were unable to identify association of the triallelic 5-HTTLPR with schizophrenia, neurocognition, or core psychotic symptoms even at levels of significance unadjusted for multiple comparisons...
  27. ncbi Neurocognition in early-onset schizophrenia and schizoaffective disorders
    Stephen R Hooper
    The Carolina Institute for Developmental Disabilities, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7255, USA
    J Am Acad Child Adolesc Psychiatry 49:52-60. 2010
    ....
  28. ncbi Clozapine as a first treatment for schizophrenia
    Margaret G Woerner
    Department of Psychiatry, Zucker Hillside Hospital of the North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA
    Am J Psychiatry 160:1514-6. 2003
    ..The authors' goal was to explore whether clozapine given as the first antipsychotic treatment favorably affects the course of schizophrenia...
  29. ncbi Aripiprazole versus haloperidol treatment in early-stage schizophrenia
    Ragy R Girgis
    Department of Psychiatry, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA
    J Psychiatr Res 45:756-62. 2011
    ..However, excessive dosing of the antipsychotic medications, in particular haloperidol, may have played an important role in accounting for the differences between aripiprazole and haloperidol in this study...
  30. ncbi Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia
    S Kristian Hill
    Center for Cognitive Medicine, Department of Psychiatry, University of Illinois at Chicago, Chicago, Illinois 60612, USA
    J Int Neuropsychol Soc 14:209-21. 2008
    ....
  31. ncbi Impairments in perceptual competency and maintenance on a visual delayed match-to-sample test in first-episode schizophrenia
    Todd Lencz
    Department of Psychiatry, The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY, USA
    Arch Gen Psychiatry 60:238-43. 2003
    ..It was hypothesized that patients in the first episode of schizophrenia would exhibit dissociable deficits in both WM domains...
  32. ncbi Auditory P300 in high-risk, recent-onset and chronic schizophrenia
    Odin van der Stelt
    Department of Psychiatry, School of Medicine, University of North Carolina, USA
    Schizophr Res 77:309-20. 2005
    ....
  33. ncbi Identifying clinically questionable psychotropic prescribing practices for medicaid recipients in new york state
    Susan M Essock
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York City, USA
    Psychiatr Serv 60:1595-602. 2009
    ..This study sought to identify and characterize rates of clinically questionable prescribing in New York State...
  34. ncbi Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations
    T Scott Stroup
    Department of Psychiatry, University of North Carolina at Chapel Hill, CB 7160, Chapel Hill, North Carolina 27599 7160, USA
    Nat Rev Drug Discov 5:133-46. 2006
    ..Practical and large, simple trials that evaluate the comparative effectiveness of antipsychotic drugs in real-world settings can help to meet these needs once a drug has reached the market...
  35. ncbi Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis
    Diana O Perkins
    Department of Psychiatry, University of North Carolina School of Medicine, CB 7160, Chapel Hill, NC 27599, USA
    Am J Psychiatry 162:1785-804. 2005
    ..The authors reviewed the literature on the association of duration of untreated psychosis with symptom severity at first treatment contact and with treatment outcomes and conducted a meta-analysis examining these relationships...
  36. ncbi Oxytocin, dopamine, and the amygdala: a neurofunctional model of social cognitive deficits in schizophrenia
    Andrew J Rosenfeld
    Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York, NY 10032, USA
    Schizophr Bull 37:1077-87. 2011
    ..The model comprises abnormalities in oxytocinergic and dopaminergic signaling in the amygdala that result in impaired emotional salience processing with consequent social cognitive deficits...
  37. ncbi A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia
    Jeffrey A Lieberman
    Department of Psychiatry, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA
    Neuropsychopharmacology 34:1322-9. 2009
    ..6 and 3.0% of patients in these groups, respectively. Memantine showed no efficacy as an adjunctive therapy in schizophrenia patients with residual psychopathology and was associated with a higher incidence of AEs than placebo...
  38. ncbi Attentional modulation of early-stage visual processing in schizophrenia
    Odin van der Stelt
    Department of Psychiatry, University of North Carolina, School of Medicine, Chapel Hill, NC 28223, USA
    Brain Res 1125:194-8. 2006
    ..These results suggest that a relatively early stage of visual-selective processing in posterior extrastriate cortex is disrupted in schizophrenia...
  39. ncbi Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1
    Jonathan M Meyer
    Department of Psychiatry, University of California, San Diego, USA
    Schizophr Res 101:273-86. 2008
    ..Given concerns over antipsychotic metabolic effects, this analysis explored MS status and outcomes in phase 1 of the CATIE Schizophrenia Trial...
  40. ncbi Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE)
    Jeffrey A Lieberman
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute, New York, NY 10032, USA
    Arch Gen Psychiatry 63:1069-72. 2006
  41. ncbi Neonatal neurosteroid administration alters parvalbumin expression and neuron number in medial dorsal thalamus of adult rats
    Samantha S Gizerian
    Curriculum in Neurobiology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA
    Brain Res 1012:66-74. 2004
    ....
  42. ncbi Apoptotic mechanisms and the synaptic pathology of schizophrenia
    Leisa A Glantz
    Department of Psychiatry, University of North Carolina-Chapel Hill, CB# 7160, Chapel Hill, NC 27599-7160, USA
    Schizophr Res 81:47-63. 2006
    ..This paper will review converging lines of data that implicate synaptic deficits in the pathophysiology of schizophrenia and propose an underlying role for apoptotic dysregulation...
  43. ncbi Interrelationships of psychiatric symptom severity, medical comorbidity, and functioning in schizophrenia
    Lydia A Chwastiak
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    Psychiatr Serv 57:1102-9. 2006
    ....
  44. ncbi Caspase-3 activation in rat frontal cortex following treatment with typical and atypical antipsychotics
    L Fredrik Jarskog
    Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7160, USA
    Neuropsychopharmacology 32:95-102. 2007
    ..Although the association between antipsychotic treatment and increased pro-apoptotic caspase-3 is intriguing, further study is needed to understand its potential effects...
  45. ncbi Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia
    Miranda H Chakos
    University of North Carolina at Chapel Hill-CB 7160, Chapel Hill, North Carolina 27599-7160, USA
    Br J Psychiatry 186:26-31. 2005
    ..early illness, after controlling for illness severity and age, supports the hypothesis of progressive hippocampal reduction in males with schizophrenia. Atypical antipsychotics early in illness may protect against this...
  46. ncbi Schizophrenia, VI: Treatments
    Jeffrey A Lieberman
    UT Southwestern Medical Center, Department of Psychiatry, Dallas TX 75390-9070, USA
    Am J Psychiatry 160:1748. 2003
  47. ncbi Perinatal flunitrazepam exposure causes persistent alteration of parvalbumin-immunoreactive interneuron localization in rat prefrontal cortex
    A Chistina Grobin
    Department of Psychiatry, Pharmacology and Bowles Center for Alcohol Studies, CB 7160, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7178, USA
    Neurosci Lett 359:9-12. 2004
    ..These data are consistent with altered distribution of a subset of interneurons after benzodiazepine exposure and suggest a role for GABAA receptor modulation in normal development of GABAergic systems in PFC...
  48. ncbi Cost-effectiveness measures, methods, and policy implications from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for schizophrenia
    Robert A Rosenheck
    Department of Psychiatry, Yale University School of Medicine and VA Northeast Program Evaluation Center, West Haven, Conn, USA
    J Clin Psychiatry 68:e05. 2007
    ....
  49. ncbi Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection
    Jeffrey A Lieberman
    Department of Psychiatry, Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute, 1051 Riverside Dr, Unit 4, New York, NY 10032, USA
    Pharmacol Rev 60:358-403. 2008
    ....
  50. ncbi Science and recovery in schizophrenia
    Jeffrey A Lieberman
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY, USA
    Psychiatr Serv 59:487-96. 2008
    ..Future clinical and neuroscience research and service development should emphasize measures of recovery as outcomes for people with schizophrenia...
  51. ncbi Teaching trainees to negotiate research collaborations with industry: a mentorship model
    David B Merrill
    Department of Psychiatry, Columbia University, College of Physicians, NY 10032, USA
    Am J Psychiatry 167:381-6. 2010
    ....
  52. ncbi Schizophrenia: new pathological insights and therapies
    L Fredrik Jarskog
    Department of Psychiatry, Schizophrenia Research Center, University of North Carolina Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Annu Rev Med 58:49-61. 2007
    ..This review provides an update on developments in research on the neuropathology of schizophrenia and discusses recent advances in antipsychotic treatment and the potential impact on long-term outcomes...
  53. ncbi Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies
    R Grant Steen
    Department of Psychiatry, University of North Carolina at Chapel Hill, Campus Box 7160, Chapel Hill, North Carolina 27599 7160, USA
    Br J Psychiatry 188:510-8. 2006
    ..Studies of people with schizophrenia assessed using magnetic resonance imaging (MRI) usually include patients with first-episode and chronic disease, yet brain abnormalities may be limited to those with chronic schizophrenia...
  54. ncbi Signaling pathways in schizophrenia: emerging targets and therapeutic strategies
    Caline S Karam
    Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    Trends Pharmacol Sci 31:381-90. 2010
    ..These include genes in the 22q11 locus, DISC1, Neuregulin 1/ErbB4, and components of the Akt/GSK-3 pathway...
  55. ncbi Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis
    Karen A Graham
    Department of Psychiatry, University of North Carolina at Chapel Hill, 27599, USA
    Am J Psychiatry 162:118-23. 2005
    ....
  56. ncbi Revised PORT recommendations
    T Scott Stroup
    University of North Carolina at Chapel Hill, 10626 Neurosciences Hospital, Campus Box #7160, Chapel Hill, NC 27599-7160, USA
    Schizophr Bull 30:609-11. 2004
  57. ncbi Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function
    Gary E Duncan
    Department of Psychiatry, University of North Carolina School of Medicine, CB 7090, Chapel Hill, NC 27599 7090, USA
    Behav Brain Res 153:507-19. 2004
    ..The NR1 hypomorphic mice could represent a model system to explore novel treatment and preventative strategies for certain symptoms of schizophrenia...
  58. ncbi Neuroprotection in schizophrenia
    L Fredrik Jarskog
    Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, USA
    J Clin Psychiatry 67:e09. 2006
    ....
  59. ncbi Components and correlates of family burden in schizophrenia
    Deborah A Perlick
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    Psychiatr Serv 57:1117-25. 2006
    ..Components and correlates of caregiver burden in schizophrenia were studied...
  60. ncbi Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol
    Jeffrey A Lieberman
    Department of Psychiatry, University of North Carolina School of Medicine, NC 27599 7160, USA
    Am J Psychiatry 160:1396-404. 2003
    ..This study compared the acute and long-term effectiveness of haloperidol with that of olanzapine in patients with first-episode psychosis in a large, controlled clinical trial...
  61. ncbi Neural correlates of automatic and controlled auditory processing in schizophrenia
    Rajendra A Morey
    Duke UNC Brain Imaging and Analysis Center, Department of Psychiatry, Duke University, Box 3918, Durham, NC 27707, USA
    J Neuropsychiatry Clin Neurosci 20:419-30. 2008
    ..Differences in activation between these two modes of auditory information processing were more pronounced in the comparison group than in the patient group...
  62. ncbi Regional gray matter growth, sexual dimorphism, and cerebral asymmetry in the neonatal brain
    John H Gilmore
    UNC Schizophrenia Research Center and Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    J Neurosci 27:1255-60. 2007
    ..These findings also indicate that whereas some adult patterns of sexual dimorphism and cerebral asymmetries are present at birth, others develop after birth...
  63. ncbi Psychosocial treatment for first-episode psychosis: a research update
    David L Penn
    Department of Psychology, CB 3270, Davie Hall, University of North Carolina Chapel Hill, Chapel Hill, NC 27599 3270, USA
    Am J Psychiatry 162:2220-32. 2005
    ..This article reviews research on psychosocial treatment for first-episode psychosis...
  64. ncbi The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development
    T Scott Stroup
    Department of Psychiatry, University of North Carolina School of Medicine, Neurosciences Hospital, Chapel Hill 27599 7160, USA
    Schizophr Bull 29:15-31. 2003
    ..If the phase 2 study drug is discontinued, subjects may enter phase 3, in which clinicians help subjects select an open-label treatment based on individuals' experiences in phases 1 and 2...
  65. ncbi Dopamine partial agonists: a new class of antipsychotic
    Jeffrey A Lieberman
    University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599 7160, USA
    CNS Drugs 18:251-67. 2004
    ..In conclusion, the findings from clinical studies of aripiprazole show that dopamine partial agonists offer a novel, effective and well-tolerated treatment approach for patients with schizophrenia...
  66. ncbi The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition
    James J Crowley
    Department of Genetics, University of North Carolina at Chapel Hill, North Carolina 27599 7264, USA
    Am J Med Genet B Neuropsychiatr Genet 147:1298-300. 2008
    ..We were unable to replicate previous associations of rs6994992 with schizophrenia and, moreover, did not find significant associations with age of onset, an estimate of pre-morbid IQ, or neurocognition...
  67. ncbi Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation
    L Fredrik Jarskog
    Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill 27599 7160, USA
    Am J Psychiatry 161:109-15. 2004
    ..It was hypothesized that the Bax/Bcl-2 ratio, but not caspase-3, would be high in the temporal cortex of patients with chronic schizophrenia...
  68. ncbi Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study
    T Scott Stroup
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC
    Am J Psychiatry 164:415-27. 2007
    ..This randomized, double-blind study compared olanzapine, quetiapine, and risperidone in patients who had just discontinued the older antipsychotic perphenazine...
  69. ncbi Striatal volume changes in the rat following long-term administration of typical and atypical antipsychotic drugs
    Candace Andersson
    Department of Psychiatry, University of North Carolina, Chapel Hill, NC 27599, USA
    Neuropsychopharmacology 27:143-51. 2002
    ..The current data suggests that such differential responses may be due to both the pharmacological properties and the relative doses of the atypical agents...
  70. ncbi Macroscopic fast neuronal oscillations and synchrony in schizophrenia
    Odin van der Stelt
    Department of Psychiatry, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA
    Proc Natl Acad Sci U S A 101:17567-8. 2004
  71. ncbi Chronic administration of haloperidol and olanzapine attenuates ketamine-induced brain metabolic activation
    Gary E Duncan
    Department of Psychiatry, CB 7090, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7250, USA
    J Pharmacol Exp Ther 305:999-1005. 2003
    ....
  72. ncbi Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis
    R Grant Steen
    Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7160, USA
    Neuropsychopharmacology 30:1949-62. 2005
    ..Only three of 64 studies included enough subjects to have 80% power to detect a 10% NAA reduction in patients, and no studies were adequately powered to detect a 5% NAA reduction with 80% power...
  73. ncbi Guest editors' introduction: what can large pragmatic clinical trials do for public mental health care?
    Jeffrey A Lieberman
    Department of Psychiatry, University of North Carolina School of Medicine, Neurosciences Hospital, Chapel Hill, NC 27599 7160, USA
    Schizophr Bull 29:1-6. 2003
  74. ncbi Olanzapine versus risperidone in newly admitted acutely ill psychotic patients
    John E Kraus
    Adult Admissions Psychiatry, Dorothea Dix Hospital, 3601 Mail Service Center, Raleigh, N C 27699 3601, USA
    J Clin Psychiatry 66:1564-8. 2005
    ..This outcome was selected as it is an indirect measure of how well patients are responding to the medication and represents a "real world" endpoint relevant to practicing hospital psychiatrists...
  75. ncbi Developmental effects of prenatal cocaine exposure on 5-HT1A receptors in male and female rat offspring
    Josephine M Johns
    Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7096, USA
    Dev Neurosci 24:522-30. 2002
    ..This study also demonstrates gender-specific development of serotonin (5-HT(1A)) receptors across postnatal ages, demonstrating a fundamentally different pattern of development of 5-HT(1A) receptors between males and females...
  76. ncbi Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study
    Linmarie Sikich
    University of North Carolina at Chapel Hill, NC 27514, USA
    Am J Psychiatry 165:1420-31. 2008
    ....
  77. ncbi Perinatal neurosteroid levels influence GABAergic interneuron localization in adult rat prefrontal cortex
    A Chistina Grobin
    Department of Psychiatry, and Bowles Center for Alcohol Studies, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7178, USA
    J Neurosci 23:1832-9. 2003
    ..These data are consistent with a change in the distribution of a subset of interneurons in response to neurosteroid exposure and suggest that GABAergic neurosteroids are critical for normal development of GABAergic systems in the PFC...
  78. ncbi Apoptotic mechanisms in the pathophysiology of schizophrenia
    L Fredrik Jarskog
    Department of Psychiatry, Schizophrenia Research Center, University of North Carolina Chapel Hill, CB 7160, Chapel Hill, NC 27599 7160, USA
    Prog Neuropsychopharmacol Biol Psychiatry 29:846-58. 2005
    ..Although the exact role of apoptosis in schizophrenia remains uncertain, the potential involvement of non-lethal localized apoptosis is intriguing, especially in earlier stages of the illness...
  79. ncbi Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder
    Robert M Bilder
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Am J Psychiatry 159:1018-28. 2002
    ....
  80. ncbi Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia
    Robert M Bilder
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Biol Psychiatry 52:701-7. 2002
    ....
  81. ncbi Relationship of cognition and psychopathology to functional impairment in schizophrenia
    Somaia Mohamed
    New England Mental Illness, Research, Education and Clinical Center, Department of Veterans Affairs, West Haven, Conn 06516, USA
    Am J Psychiatry 165:978-87. 2008
    ..This study evaluated the association of neurocognition and symptoms with measures of social and occupational functioning in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)...
  82. ncbi Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study
    Bruce J Kinon
    Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 28:392-400. 2008
    ....
  83. ncbi Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial
    David L Sultzer
    Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA
    Am J Psychiatry 165:844-54. 2008
    ..The study measured the effects of atypical antipsychotics on psychiatric and behavioral symptoms in patients with Alzheimer's disease and psychosis or agitated behavior...
  84. ncbi Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder
    Delbert G Robinson
    Department of Psychiatry Research, Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, New York 11004, USA
    Schizophr Res 57:209-19. 2002
    ..Although extensively studied in multi-episode patients, little data exist on medication adherence by first-episode patients...
  85. ncbi What CATIE found: results from the schizophrenia trial
    Marvin S Swartz
    Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC 27710, USA
    Psychiatr Serv 59:500-6. 2008
    ..Patient characteristics and clinical circumstances affected drug effectiveness; these patient factors are important in making treatment choices...
  86. ncbi Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1
    Jonathan M Meyer
    Department of Psychiatry, University of California, San Diego, VA San Diego Healthcare System, San Diego, CA 92161, United States
    Schizophr Res 103:104-9. 2008
    ..Given concerns over antipsychotic effects on serum TG, this analysis explored changes in nonfasting TG in phase 1 of the CATIE Schizophrenia Trial...
  87. ncbi Cholinergic agonists as novel treatments for schizophrenia: the promise of rational drug development for psychiatry
    Jeffrey A Lieberman
    Am J Psychiatry 165:931-6. 2008
  88. ncbi The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study
    Marvin S Swartz
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham NC 27710, United States
    Schizophr Res 100:39-52. 2008
    ..This double-blind study compared a second generation (atypical) antipsychotic drugs compared to a representative older agent for patients with schizophrenia who use or avoid illicit substances...
  89. ncbi Treatment of early-onset schizophrenia spectrum disorders (TEOSS): demographic and clinical characteristics
    Jean A Frazier
    Cambridge Health Alliance, Harvard Medical School, Cambridge, MA, USA
    J Am Acad Child Adolesc Psychiatry 46:979-88. 2007
    ..We examined baseline demographic and clinical profiles of youths enrolled from 2001 to 2006 in the publicly funded multicenter, randomized controlled trial Treatment of Early-Onset Schizophrenia Spectrum Disorders...
  90. ncbi Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods
    Jon McClellan
    University of Washington, Seattle, USA
    J Am Acad Child Adolesc Psychiatry 46:969-78. 2007
    ..The rationale, design, and methods of the Treatment of Early Onset Schizophrenia Spectrum Disorders Study are described...
  91. ncbi Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol
    Robert B Zipursky
    Schizophrenia Programme, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario, Canada M5T 1R8
    Br J Psychiatry 187:537-43. 2005
    ..Substantial weight gain is common with many atypical antipsychotics...
  92. ncbi Quantitative MRI measures of orbitofrontal cortex in patients with chronic schizophrenia or schizoaffective disorder
    Matthew J Hoptman
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Psychiatry Res 140:133-45. 2005
    ..Larger left OFC gray matter volumes and larger OFC white matter volumes bilaterally were associated with greater levels of aggression. These findings are discussed in the context of potential iatrogenic effects...
  93. ncbi Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA
    Biol Psychiatry 59:97-105. 2006
    ..Neurocognitive deficits are severe in first-episode psychosis...
  94. ncbi Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode
    Stephen M Strakowski
    Center for Imaging Research and Division of Bipolar Disorders Research, University of Cincinnati College of Medicine, 231 Albert Sabin Way ML0583, Cincinnati, OH 45267 0583, USA
    Schizophr Res 78:161-9. 2005
    ..This improvement is particularly relevant early in the course of schizophrenia...
  95. ncbi Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation
    Jan Volavka
    Schizophr Res 76:127-9. 2005
  96. ncbi The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia
    Daniel J Muller
    Neurogenetics Section, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, 250 College Street R30, Toronto, Ont M5T 1R8, Canada
    Neurosci Lett 379:81-9. 2005
    ..Weight changes do not seem to be associated with polymorphism of the SNAP-25 gene, however, replication in independent samples is warranted...
  97. ncbi Imaging frontostriatal function in ultra-high-risk, early, and chronic schizophrenia during executive processing
    Rajendra A Morey
    Duke-UNC Brain Imaging and Analysis Center, Durham, NC, USA
    Arch Gen Psychiatry 62:254-62. 2005
    ....
  98. ncbi Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder
    Karen A Nolan
    Nathan Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    J Psychiatr Res 39:109-15. 2005
    ..These findings in chronic, treatment resistant inpatients support the view that positive symptoms may lead to aggression...
  99. ncbi Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder
    Jan Volavka
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10982, USA
    Am J Psychiatry 159:255-62. 2002
    ....
  100. ncbi Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol
    Jan Volavka
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10982, USA
    J Clin Psychopharmacol 24:225-8. 2004
    ..Clozapine appears to have superior antiaggresive effects in treatment-resistant patients; this superiority develops after the patient has been exposed to an adequate dose regimen...
  101. ncbi Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC 27710, USA
    Am J Psychiatry 161:985-95. 2004
    ..This study compares the neurocognitive effects of olanzapine and low doses of haloperidol in patients with first-episode psychosis...